Clinical trials: Endometrial Carcinoma
Gynecologic Cancer, Ovarian Cancer
Gyn Onc Prehab Study
Patients will be randomized to a unimodal or trimodal prehabilitation program prior to surgery for known or suspected gynecologic cancer.
- Conditions
- Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT04298827
- Testing
- Unimodal, Trimodal
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Endometrial Neoplasms
Robotic Versus Abdominal Surgery for Endometrial Cancer
This study is intended to explore differences in oncologic and surgical safety between robotic assisted laparoscopy and conventional abdominal surgery for high risk endometrial cancer.
- Trial name
- RASHEC (NCT01847703)
- Testing
- Robotic surgery, Abdominal surgery
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska Institutet
Endometrial Cancer
Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery.
Background: Endometrial cancer is one of the diseases linked to obesity in women. In Mexico, about 7.6 women out of every 100,000 are diagnosed with this type of cancer, and nearly three-quarters of these women have obesity.
- Trial name
- NCT07025213
- Testing
- Diet and exercise., Diet.
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- National Institute of Cancerología
Cervix Cancer, Endometrial Cancer
2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy
Demonstrate the limitations of conventional dosimetry (2D) for the adjuvant brachytherapy treatment and assess whether tridimensional dosimetry relates more faithfully with the occurrence of adverse effects.
- Trial name
- NCT02091050
- Testing
- 2D HDR planning, 3D HDR planning
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- AC Camargo Cancer Center
Endometrial Cancer
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030485
- Testing
- erlotinib hydrochloride
- Where
- 8 sites in Canada
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Salivary Gland Cancer
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
- Conditions
- Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squamous Cell Carcinoma of the Cervix
- Trial name
- NCT02042885
- Testing
- OPB-111001
- Where
- 2 sites in United Kingdom
- Volunteers
- 79 people
- Sponsor
- Otsuka Novel Products GmbH
Endometrial Neoplasms
Sentinel Lymph Node Mapping In Endometrial Cancer
Lymph node assessment provides the crucial information about the prognosis of endometrial cancer. Sentinel lymph node stands in the first station on the lymph node metastasis pathways.
- Trial name
- SLNMIEC (NCT03778255)
- Testing
- Sentinel Lymph Node Biopsy
- Where
- China
- Volunteers
- 635 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer
Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment
EUGENIE is a prospective multicentre interventional study, focused on improving endometrial cancer (EC) assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment.
- Trial name
- EUGENIE (NCT06354738)
- Testing
- total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Gasthuisberg
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Breast Cancer, Gastric Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry…
- Conditions
- Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
- Trial name
- NCT06695845
- Testing
- Zanidatamab
- Where
- 42 sites in United States, Georgia and 2 more
- Volunteers
- 200 people
- Sponsor
- Jazz Pharmaceuticals
SCCOHT, Ovarian Clear Cell Tumor
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.
- Conditions
- SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT04611139
- Testing
- SP-2577, Pembrolizumab
- Where
- United States
- Sponsor
- HonorHealth Research Institute
Endometrial Carcinoma, Ovarian Cancer
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed…
- Conditions
- Endometrial Carcinoma, Ovarian Cancer, Cervix Cancer
- Trial name
- ANGELICA (NCT07146919)
- Testing
- Bemarituzumab, Bevacizumab
- Sponsor
- Centre Leon Berard
Pelvic Neoplasms
Treatment of Hemorrhagic Radiation Proctitis Using the Halo System
This study involves evaluating a procedure in which the study device, the HALO90 Ablation catheter, is used to heat a thin layer of tissue lining the rectum using radiofrequency (RF) energy in subjects suffering from radiation…
- Trial name
- NCT01103492
- Testing
- HALO90 Ablation catheter
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Endometrial Carcinoma
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
- Trial name
- NCT00334295
- Testing
- Fulvestrant
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Endometrial Cancer, Cervical Cancer
Tachosil for the Prevention of Symptomatic Lymph Cysts
This is a randomized trial of 140 women with endometrial or cervical cancer undergoing removal of lymph tissue (lymphadenectomy).
- Trial name
- NCT01470677
- Testing
- Tachosil fibrin patch
- Where
- 2 sites in Austria, Germany
- Volunteers
- 220 people
- Sponsor
- Ruhr University of Bochum
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Endometrial Cancer
FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment
Endometrial cancer is the most common gynecological malignancy in the western world and its incidence is expected to increase in the coming years due to obesity.
- Trial name
- FESPET (NCT03489473)
- Testing
- 18F-FES PET CT scan
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery.
- Conditions
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02315469
- Testing
- Comprehensive Geriatric Assessment, Questionnaire Administration
- Where
- 393 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- NRG Oncology
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Serous Endometrial Intraepithalial Carcinoma, SEIC
Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study
Background: Serous endometrial intra-epithelial carcinoma (SEIC) is a rare condition affecting the lining of the uterus. It's a pre-cancerous change that might lead to cancer if not treated.
- Trial name
- SEIC (NCT06677242)
- Testing
- Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.